Abbott (NYSE: ABT), a US-based global healthcare company, announced on Friday that it is developing a new biowearable that will continuously monitor glucose and ketone levels in one sensor.

The system has secured breakthrough device designation from the US Food and Drug Administration, which is designed to expedite the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions. The glucose-ketone sensor will be the same size as Abbott's FreeStyle Libre 3 sensor, and will connect to Abbott's digital ecosystem, including personal and caregiver mobile apps and cloud-based data management software for remote monitoring by healthcare professionals.

Jared Watkin, senior vice president of Abbott's diabetes care business, said, 'Abbott revolutionised diabetes care with FreeStyle Libre technology, which is the number one continuous glucose monitor used by 4 million people around the world. We're designing our glucose-ketone monitoring system with superior sensing technology that will pair with industry-leading insulin pumps to create a best-in-class solution. We're optimistic that this will be the next big advancement in diabetes tech and a breakthrough for people with diabetes, especially those who are at risk of developing diabetic ketoacidosis.'